Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 4/20 | 0.38 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 4/20 | 0.33 |
| ▸ | RXRA | P19793 | 1/20 | 0.33 |
| ▸ | RXRB | P28702 | 1/20 | 0.33 |
| ▸ | MMP13 | P45452 | 1/20 | 0.33 |
| ▸ | LOX | P28300 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | JMJD6 | Q6NYC1 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6845498 | 0.86 | MAPT (0.41) | CYP26A1CYP3A4RXRARXRBNPC1 | |
| SCHEMBL6212000 | 0.85 | NPC1 (0.46) | RXRARXRBNPC1POLBRAB9A | |
| SCHEMBL6842617 | 0.85 | MMP13 (0.44) | LOXL2MMP13LOX | |
| SCHEMBL6845397 | 0.84 | THRB (0.44) | MMP13RAB9ASMN1; SMN2KDM4EMAOB | |
| SCHEMBL6843321 | 0.84 | MAPT (0.40) | RXRARXRBNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6195792 | 0.83 | LMNA (0.47) | NPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL6211286 | 0.83 | LOXL2 (0.40) | LOXL2RXRARXRBMMP13LOX | |
| SCHEMBL6843399 | 0.81 | KMT2A (0.45) | NPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL6843368 | 0.80 | RXRA (0.44) | RXRARXRBNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6843441 | 0.80 | RXRA (0.44) | RXRARXRBNPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040043983-A1 | Naphthalene derivatives as matrix metalloproteinase inhibitors | LI JIE JACK (US) | 2004-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040043983-A1 | Naphthalene derivatives as matrix metalloproteinase inhibitors | MMP9, MMP8, MMP13 | LOXL2 1024/4885CYP26A1 987/4885CYP3A4 1935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.